A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

Abstract Background Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (≤6-month of treatment) a reduction in the number of migraine headache days and improved patients’ functi...

Full description

Bibliographic Details
Main Authors: Angelo Camporeale, David Kudrow, Ryan Sides, Shufang Wang, Annelies Van Dycke, Katherine J. Selzler, Virginia L. Stauffer
Format: Article
Language:English
Published: BMC 2018-11-01
Series:BMC Neurology
Subjects:
Migraine
Headache
Galcanezumab
CGRP
Online Access:http://link.springer.com/article/10.1186/s12883-018-1193-2

Internet

http://link.springer.com/article/10.1186/s12883-018-1193-2

Similar Items